Vanda Pharmaceuticals at Cantor conference: psychiatry push takes center stage

Vanda Pharmaceuticals outlined a path to $750 million of psychiatry revenue by 2030, contingent on launching BYSANTI, converting Fanapt patients, securing an MDD label expansion and developing long-acting injectables. BYSANTI, approved in February 2026 and expected to launch by year-end, is projected to generate a mid-30% gross-to-net rate versus roughly 50% for Fanapt, whose approximately 10,000-patient base is growing about 30% year over year. Key catalysts include multiple Phase III readouts before year-end 2026, notably NEREUS for GLP-1-related nausea and vomiting, where Phase II reduced vomiting from more than 60% on placebo to about 30%; BYSANTI MDD data were delayed to H1 2027. The outlook is constructive but execution-dependent, particularly given VNDA shares have fallen 45.75% over six months and 42.86% year to date.

Analysis

VNDA’s investable near-term issue is not the nominal launch count but whether it can preserve psychiatry revenue through Fanapt’s late-2027 loss of exclusivity while improving net price. A successful conversion to BYSANTI could lift net revenue per retained patient by roughly 30% versus Fanapt’s current rebate burden, but this is a payer- and prescriber-behavior assumption rather than incremental demand. The key downside is that payers treat bioequivalence as an invitation to steer patients to lower-cost generic alternatives, turning the proposed switch into a revenue-defense exercise with higher commercial spend rather than a margin expansion event.

The year-end readouts create an unusually dense binary-catalyst calendar for a sub-$0.5bn biotech. NEREUS in GLP-1-related nausea is the highest convexity asset, but the market may be overestimating its addressable market: intermittent use around dose escalation limits annual prescriptions per patient, and GLP-1 manufacturers have a strong incentive to improve tolerability internally or bundle antiemetic support. A positive trial therefore supports a re-rating, but meaningful revenue likely remains a 2028+ event given supplemental filing, label negotiations, and reimbursement execution.

Consensus appears anchored to the 2030 psychiatry aspiration without appropriately discounting the clinical, launch, and genericization dependencies. The more immediate valuation catalyst is verifiable: quarterly BYSANTI new-starts, Fanapt-to-BYSANTI conversion, and consolidated gross-to-net. The MDD timing slip raises development-execution risk and removes a 2026 catalyst; absent disclosed launch metrics, conference commentary alone is insufficient to underwrite a durable rerating.

Key Decisions for Investors

• Maintain VNDA as a catalyst watch rather than establish a core long before year-end data. Initiate only if management discloses early BYSANTI conversion/new-start metrics and consolidated gross-to-net improves without an outsized SG&A step-up; reassess after the next earnings release.
• For event-driven capital, consider a small defined-risk VNDA call spread spanning the NEREUS Phase III readout rather than common equity exposure. Size for a binary outcome; take profits on a post-data spike unless the company provides a credible sNDA timetable and reimbursement pathway.
• Avoid underwriting the $750m psychiatry outcome in base-case valuation until switching is demonstrated. Falsification threshold for the bullish thesis: sequential Fanapt/BYSANTI net product revenue fails to stabilize by mid-2027, or payer restrictions materially increase gross-to-net above management’s mid-30% expectation.
• Monitor GLP-1 sponsor disclosures from LLY and NVO for GI-tolerability improvements, dose-escalation changes, or companion-treatment initiatives. Any evidence of lower discontinuation from nausea/vomiting reduces NEREUS’s strategic value before its Phase III result.